No quarterly revenue total was found in DiaMedica Therapeutics Inc.'s SEC filings.
DiaMedica Therapeutics Inc. (DMAC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$8.1 million. As of Jun 30, 2026 it held $43.5 million in cash and investments and $185,000 in total debt.
Revenue
—
Net income
$-10.14M
-31.7% vs year-ago quarter
Operating cash flow
$-8.11M
-6.8% vs year-ago quarter
Free cash flow
$-8.12M
-6.7% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
53.93M
+4.3% vs year-ago quarter
Net cash
$43.32M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMAC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Minneapolis, MN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1401040
- Former names
- DiaMedica Inc. (until Mar 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$10.5M | -$10.5M | -$9.2M | -$9.0M | -$8.0M |
| Net income | -$10.1M | -$10.0M | -$8.7M | -$8.6M | -$7.7M |
| Operating cash flow | -$8.1M | -$9.1M | -$7.8M | -$6.5M | -$7.6M |
| Free cash flow | -$8.1M | -$9.1M | -$7.8M | -$6.6M | -$7.6M |
| Total assets | $45.0M | $53.1M | $61.4M | $57.0M | $31.5M |
| Stockholders' equity | $38.3M | $47.2M | $56.1M | $51.6M | $27.2M |
| Cash and investments | $43.5M | $51.3M | $59.9M | $55.3M | $30.0M |
| Total debt | $185,000 | $212,000 | $240,000 | $266,000 | $292,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| ARS | Annual report to shareholders | Apr 1, 2026 | Dec 31, 2025 |
All 427 DiaMedica Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.